Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
- Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth
- Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25
- Initiates full year 2024 guidance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter 2023
The Company reported GAAP earnings per share of $0.64, as compared to $1.01 in the same period a year ago. GAAP revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $77 million, as compared to $137 million for the same period a year ago. GAAP operating profit margin from continuing operations was 11.1% as a percentage of revenue, as compared to 18.5% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.25, as compared to $1.41 in the same period a year ago. Adjusted revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. Adjusted operating income was $192 million, as compared to $240 million for the same period a year ago. Adjusted operating profit margin was 27.5% as a percentage of adjusted revenue, as compared to 32.3% in the same period a year ago.
Full Year 2023
The Company reported GAAP earnings per share of $5.55 in 2023, as compared to $4.50 in 2022. GAAP revenue for the year was $2,751 million, as compared to $3,312 million in 2022. GAAP operating income from continuing operations for the year was $301 million, as compared to $743 million for 2022. GAAP operating profit margin from continuing operations for the year was 10.9% as a percentage of revenue, as compared to 22.4% in 2022.
Adjusted earnings per share from continuing operations for the year was $4.65, as compared to $6.92 in 2022. Adjusted revenue for the year was $2,751 million, as compared to $3,313 million in 2022. Adjusted operating income for the year was $770 million, as compared to $1,212 million in 2022. Adjusted operating profit margin for the year was 28.0% as a percentage of adjusted revenue, as compared to 36.6% in 2022.
Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.
“We persevered through continued industry headwinds and performed better than anticipated during the final months of 2023,” said Prahlad Singh, president and chief executive officer of Revvity. “We are leading with innovation to be a strategic scientific partner with our customers, which positions us well to continue to perform at a high level for years to come.”
Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2023
Life Sciences
- Fourth quarter 2023 revenue was $320 million, as compared to $347 million in the same period a year ago. Reported revenue decreased 8% and organic revenue decreased 9% as compared to the same period a year ago.
- Full year 2023 revenue was $1,292 million, as compared to $1,293 million in 2022. Reported revenue and organic revenue were both flat as compared to the same period a year ago.
- Fourth quarter 2023 adjusted operating income was $118 million, as compared to $146 million in the same period a year ago. Adjusted operating profit margin was 36.9% as a percentage of adjusted revenue, as compared to 41.9% in the same period a year ago.
- Full year 2023 adjusted operating income was $489 million, as compared to $503 million in 2022. Adjusted operating profit margin was 37.9% as a percentage of adjusted revenue, as compared to 38.9% in 2022.
Diagnostics
- Fourth quarter 2023 revenue was $376 million, as compared to $394 million in the same period a year ago. Reported revenue decreased 4% and organic revenue decreased 6% as compared to the same period a year ago.
- Full year 2023 revenue was $1,459 million, as compared to $2,020 million in 2022. Reported revenue decreased 28% and organic revenue decreased 27% as compared to the same period a year ago.
- Fourth quarter 2023 adjusted operating income was $80 million, as compared to $113 million in the same period a year ago. Adjusted operating profit margin was 21.1% as a percentage of adjusted revenue, as compared to 28.7% in the same period a year ago.
- Full year 2023 adjusted operating income was $321 million, as compared to $782 million in 2022. Adjusted operating profit margin was 22.0% as a percentage of adjusted revenue, as compared to 38.7% in 2022.
Initiates Full Year 2024 Guidance
For the full year 2024, the Company forecasts total revenue of $2.79-$2.85 billion and adjusted earnings per share of $4.55-$4.75.
Guidance for the full year 2024 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.
Webcast Information
The Company will discuss its fourth quarter and full year 2023 results and its outlook for business trends during a webcast on February 1, 2024, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Revvity, Inc. and Subsidiaries | ||||||||||||||||||
CONDENSED CONSOLIDATED INCOME STATEMENTS | ||||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||
(In thousands, except per share data) | December 31, 2023 | January 1, 2023 | December 31, 2023 | January 1, 2023 | ||||||||||||||
Revenue | $ | 695,901 |
| $ | 741,214 |
| $ | 2,750,571 |
| $ | 3,311,822 |
| ||||||
Cost of revenue |
| 312,423 |
|
| 304,884 |
|
| 1,210,880 |
|
| 1,321,992 |
| ||||||
Selling, general and administrative expenses |
| 256,723 |
|
| 244,325 |
|
| 1,022,551 |
|
| 1,025,514 |
| ||||||
Research and development expenses |
| 49,596 |
|
| 54,536 |
|
| 216,578 |
|
| 221,617 |
| ||||||
Operating income from continuing operations |
| 77,159 |
|
| 137,469 |
|
| 300,562 |
|
| 742,699 |
| ||||||
Interest income |
| (18,363 | ) |
| (1,565 | ) |
| (72,131 | ) |
| (3,589 | ) | ||||||
Interest expense |
| 24,582 |
|
| 22,508 |
|
| 98,813 |
|
| 103,955 |
| ||||||
Change in fair value of financial securities |
| 21,079 |
|
| 1,433 |
|
| 33,921 |
|
| 15,754 |
| ||||||
Other expense (income), net |
| 18,482 |
|
| (23,354 | ) |
| 56,983 |
|
| (25,258 | ) | ||||||
Income from continuing operations, before income taxes |
| 31,379 |
|
| 138,447 |
|
| 182,976 |
|
| 651,837 |
| ||||||
(Benefit from) provision for income taxes |
| (32,188 | ) |
| 40,950 |
|
| 3,473 |
|
| 139,161 |
| ||||||
Income from continuing operations |
| 63,567 |
|
| 97,497 |
|
| 179,503 |
|
| 512,676 |
| ||||||
Income from discontinued operations |
| 14,996 |
|
| 30,161 |
|
| 513,591 |
|
| 56,503 |
| ||||||
Net income | $ | 78,563 |
| $ | 127,658 |
| $ | 693,094 |
| $ | 569,179 |
| ||||||
Diluted earnings per share: | ||||||||||||||||||
Income from continuing operations | $ | 0.52 |
| $ | 0.77 |
| $ | 1.44 |
| $ | 4.06 |
| ||||||
Income from discontinued operations |
| 0.12 |
|
| 0.24 |
|
| 4.11 |
|
| 0.45 |
| ||||||
Net income | $ | 0.64 |
| $ | 1.01 |
| $ | 5.55 |
| $ | 4.50 |
| ||||||
Weighted average diluted shares of common stock outstanding |
| 123,412 |
|
| 126,476 |
|
| 124,812 |
|
| 126,426 |
| ||||||
ABOVE PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||||
Additional supplemental information (1): | ||||||||||||||||||
(per share, continuing operations) | ||||||||||||||||||
GAAP EPS from continuing operations | $ | 0.52 |
| $ | 0.77 |
| $ | 1.44 |
| $ | 4.06 |
| ||||||
Amortization of intangible assets |
| 0.73 |
|
| 0.71 |
|
| 2.93 |
|
| 2.93 |
| ||||||
Debt extinguishment costs |
| (0.00 | ) |
| (0.02 | ) |
| (0.03 | ) |
| (0.02 | ) | ||||||
Purchase accounting adjustments |
| 0.02 |
|
| 0.00 |
|
| 0.05 |
|
| 0.36 |
| ||||||
Acquisition and divestiture-related costs |
| 0.08 |
|
| 0.11 |
|
| 0.71 |
|
| 0.32 |
| ||||||
Change in fair value of financial securities |
| 0.17 |
|
| 0.01 |
|
| 0.27 |
|
| 0.12 |
| ||||||
Significant litigation matters and settlements |
| 0.00 |
|
| 0.00 |
|
| 0.00 |
|
| (0.00 | ) | ||||||
Significant environmental matters |
| 0.01 |
|
| - |
|
| 0.02 |
|
| - |
| ||||||
Disposition of businesses and assets, net |
| - |
|
| (0.02 | ) |
| - |
|
| (0.02 | ) | ||||||
Mark to market on postretirement benefits |
| 0.08 |
|
| (0.18 | ) |
| 0.08 |
|
| (0.18 | ) | ||||||
Restructuring and other, net |
| 0.09 |
|
| (0.01 | ) |
| 0.21 |
|
| 0.11 |
| ||||||
Tax on above items |
| (0.29 | ) |
| (0.07 | ) |
| (1.02 | ) |
| (0.84 | ) | ||||||
Significant tax items |
| (0.14 | ) |
| 0.12 |
|
| (0.01 | ) |
| 0.10 |
| ||||||
Adjusted EPS from continuing operations | $ | 1.25 |
| $ | 1.41 |
| $ | 4.65 |
| $ | 6.92 |
| ||||||
(1) amounts may not sum due to rounding | ||||||||||||||||||
| Revvity, Inc. and Subsidiaries | ||||||||||||||||
REVENUE AND OPERATING INCOME (LOSS) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
| (In thousands, except percentages) | December 31, 2023 | January 1, 2023 | December 31, 2023 | January 1, 2023 | ||||||||||||
| Adjusted revenue and operating income | ||||||||||||||||
| Reported revenue | $ | 695,901 |
| $ | 741,214 |
| $ | 2,750,571 |
| $ | 3,311,822 |
| ||||
| Revenue purchase accounting adjustments |
| 209 |
|
| 205 |
|
| 827 |
|
| 814 |
| ||||
| Adjusted revenue |
| 696,110 |
|
| 741,419 |
|
| 2,751,398 |
|
| 3,312,636 |
| ||||
| Reported operating income from continued operations |
| 77,159 |
|
| 137,469 |
|
| 300,562 |
|
| 742,699 |
| ||||
| OP% |
| 11.1 | % |
| 18.5 | % |
| 10.9 | % |
| 22.4 | % | ||||
| Amortization of intangible assets |
| 89,624 |
|
| 90,169 |
|
| 365,113 |
|
| 370,638 |
| ||||
| Purchase accounting adjustments |
| 2,899 |
|
| 87 |
|
| 5,956 |
|
| 45,681 |
| ||||
| Acquisition and divestiture-related costs |
| 10,079 |
|
| 13,961 |
|
| 69,159 |
|
| 39,826 |
| ||||
| Significant litigation matters and settlements |
| 12 |
|
| 5 |
|
| 12 |
|
| (627 | ) | ||||
| Significant environmental matters |
| 1,325 |
|
| - |
|
| 2,457 |
|
| - |
| ||||
| Restructuring and other, net |
| 10,665 |
|
| (1,863 | ) |
| 26,601 |
|
| 13,580 |
| ||||
| Adjusted operating income | $ | 191,763 |
| $ | 239,828 |
| $ | 769,860 |
| $ | 1,211,797 |
| ||||
| OP% |
| 27.5 | % |
| 32.3 | % |
| 28.0 | % |
| 36.6 | % | ||||
| Segment revenue and segment operating income | ||||||||||||||||
| Life Sciences | $ | 319,691 |
| $ | 347,425 |
| $ | 1,292,340 |
| $ | 1,292,909 |
| ||||
| Diagnostics |
| 376,419 |
|
| 393,994 |
|
| 1,459,058 |
|
| 2,019,727 |
| ||||
| Revenue purchase accounting adjustments |
| (209 | ) |
| (205 | ) |
| (827 | ) |
| (814 | ) | ||||
| Reported revenue |
| 695,901 |
|
| 741,214 |
|
| 2,750,571 |
|
| 3,311,822 |
| ||||
| Life Sciences |
| 117,939 |
|
| 145,582 |
|
| 489,349 |
|
| 503,243 |
| ||||
| 36.9 | % |
| 41.9 | % |
| 37.9 | % |
| 38.9 | % | |||||
| Diagnostics |
| 79,514 |
|
| 113,004 |
|
| 320,928 |
|
| 781,985 |
| ||||
| 21.1 | % |
| 28.7 | % |
| 22.0 | % |
| 38.7 | % | |||||
| Corporate |
| (5,690 | ) |
| (18,758 | ) |
| (40,417 | ) |
| (73,431 | ) | ||||
| Subtotal reportable segments adjusted operating income |
| 191,763 |
|
| 239,828 |
|
| 769,860 |
|
| 1,211,797 |
| ||||
| Amortization of intangible assets |
| (89,624 | ) |
| (90,169 | ) |
| (365,113 | ) |
| (370,638 | ) | ||||
| Purchase accounting adjustments |
| (2,899 | ) |
| (87 | ) |
| (5,956 | ) |
| (45,681 | ) | ||||
| Acquisition and divestiture-related costs |
| (10,079 | ) |
| (13,961 | ) |
| (69,159 | ) |
| (39,826 | ) | ||||
| Significant litigation matters and settlements |
| (12 | ) |
| (5 | ) |
| (12 | ) |
| 627 |
| ||||
| Significant environmental matters |
| (1,325 | ) |
| - |
|
| (2,457 | ) |
| - |
| ||||
| Restructuring and other, net |
| (10,665 | ) |
| 1,863 |
|
| (26,601 | ) |
| (13,580 | ) | ||||
| Reported operating income from continued operations | $ | 77,159 |
| $ | 137,469 |
| $ | 300,562 |
| $ | 742,699 |
| ||||
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||
| Revvity, Inc. and Subsidiaries | ||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (In thousands) | December 31, 2023 | January 1, 2023 | ||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 913,163 | $ | 454,358 | ||
| Marketable securities |
| 689,916 |
| - | ||
| Accounts receivable, net |
| 632,811 |
| 612,780 | ||
| Inventories, net |
| 428,062 |
| 405,462 | ||
| Other current assets |
| 337,139 |
| 122,254 | ||
| Current assets of discontinued operations |
| - |
| 1,693,704 | ||
| Total current assets |
| 3,001,091 |
| 3,288,558 | ||
| Property, plant and equipment, net |
| 509,654 |
| 482,950 | ||
| Operating lease right-of-use assets, net |
| 155,083 |
| 188,351 | ||
| Intangible assets, net |
| 3,022,321 |
| 3,377,174 | ||
| Goodwill |
| 6,533,550 |
| 6,481,768 | ||
| Other assets, net |
| 342,966 |
| 311,054 | ||
| Total assets | $ | 13,564,665 | $ | 14,129,855 | ||
| Current liabilities: | ||||||
| Current portion of long-term debt | $ | 721,872 | $ | 470,929 | ||
| Accounts payable |
| 204,121 |
| 272,826 | ||
| Accrued expenses and other current liabilities |
| 524,470 |
| 527,863 | ||
| Current liabilities of discontinued operations |
| - |
| 272,865 | ||
| Total current liabilities |
| 1,450,463 |
| 1,544,483 | ||
| Long-term debt |
| 3,177,770 |
| 3,923,347 | ||
| Long-term liabilities |
| 930,946 |
| 1,109,181 | ||
| Operating lease liabilities |
| 132,747 |
| 169,968 | ||
| Total liabilities |
| 5,691,926 |
| 6,746,979 | ||
| Total stockholders' equity |
| 7,872,739 |
| 7,382,876 | ||
| Total liabilities and stockholders' equity | $ | 13,564,665 | $ | 14,129,855 | ||
PREPARED IN ACCORDANCE WITH GAAP | ||||||
| Revvity, Inc. and Subsidiaries | ||||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31, 2023 | January 1, 2023 | December 31, 2023 | January 1, 2023 | |||||||||||||
(In thousands) | (In thousands) | |||||||||||||||
| Operating activities: | ||||||||||||||||
| Net income | $ | 78,563 |
| $ | 127,658 |
| $ | 693,094 |
| $ | 569,179 |
| ||||
| Income from discontinued operations, net of income taxes |
| (14,996 | ) |
| (30,161 | ) |
| (513,591 | ) |
| (56,503 | ) | ||||
| Income from continuing operations |
| 63,567 |
|
| 97,497 |
|
| 179,503 |
|
| 512,676 |
| ||||
| Adjustments to reconcile income from continuing operations to net cash provided by (used in) continuing operations: | ||||||||||||||||
| Stock-based compensation |
| 7,181 |
|
| 11,742 |
|
| 41,410 |
|
| 51,518 |
| ||||
| Restructuring and other, net |
| 10,665 |
|
| (1,863 | ) |
| 26,601 |
|
| 13,580 |
| ||||
| Depreciation and amortization |
| 105,568 |
|
| 104,234 |
|
| 431,769 |
|
| 427,000 |
| ||||
| Pension and other postretirement expenses |
| 23,089 |
|
| (23,104 | ) |
| 23,089 |
|
| (23,104 | ) | ||||
| Change in fair value of contingent consideration |
| 2,450 |
|
| (608 | ) |
| 4,168 |
|
| (1,377 | ) | ||||
| Deferred taxes |
| (123,664 | ) |
| (105,923 | ) |
| (123,664 | ) |
| (105,923 | ) | ||||
| Contingencies and non-cash tax matters |
| 26,183 |
|
| (1,488 | ) |
| 26,183 |
|
| (1,488 | ) | ||||
| Amortization of deferred debt financing costs and accretion of discounts |
| 1,549 |
|
| 1,264 |
|
| 7,349 |
|
| 7,310 |
| ||||
| Gains on disposition of businesses and assets, net |
| - |
|
| (2,887 | ) |
| - |
|
| (2,887 | ) | ||||
| Change in fair value of financial securities |
| 21,079 |
|
| 1,433 |
|
| 33,921 |
|
| 15,754 |
| ||||
| Debt extinguishment gain |
| (263 | ) |
| (2,788 | ) |
| (3,685 | ) |
| (2,880 | ) | ||||
| Unrealized foreign exchange loss |
| 410 |
|
| - |
|
| 24,089 |
|
| - |
| ||||
| Amortization of acquired inventory revaluation |
| - |
|
| 250 |
|
| - |
|
| 45,289 |
| ||||
| Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired: | ||||||||||||||||
| Accounts receivable, net |
| 21,916 |
|
| (54,045 | ) |
| (8,997 | ) |
| 66,093 |
| ||||
| Inventories |
| 20,725 |
|
| (4,159 | ) |
| (14,109 | ) |
| (48,634 | ) | ||||
| Accounts payable |
| 8,968 |
|
| (15,836 | ) |
| (76,426 | ) |
| (43,804 | ) | ||||
| Accrued expenses and other |
| 31,181 |
|
| 123,466 |
|
| (291,814 | ) |
| (236,623 | ) | ||||
| Net cash provided by operating activities of continuing operations |
| 220,604 |
|
| 127,185 |
|
| 279,387 |
|
| 672,500 |
| ||||
| Net cash (used in) provided by operating activities of discontinued operations |
| (23,991 | ) |
| 11,973 |
|
| (188,115 | ) |
| 7,310 |
| ||||
| Net cash provided by operating activities |
| 196,613 |
|
| 139,158 |
|
| 91,272 |
|
| 679,810 |
| ||||
| Investing activities: | ||||||||||||||||
| Capital expenditures |
| (24,116 | ) |
| (26,130 | ) |
| (81,368 | ) |
| (85,632 | ) | ||||
| Purchases of investments |
| (300 | ) |
| (2,171 | ) |
| (6,300 | ) |
| (47,181 | ) | ||||
| Purchases of US Treasury Securities |
| (390,390 | ) |
| - |
|
| (1,221,609 | ) |
| - |
| ||||
| Proceeds from US Treasury Securities |
| - |
|
| 550,000 |
| ||||||||||
| Proceeds from notes receivables |
| - |
|
| - |
|
| - |
|
| 8,890 |
| ||||
| Proceeds from disposition of businesses and assets |
| - |
|
| 8,841 |
|
| 153 |
|
| 14,505 |
| ||||
| Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired |
| - |
|
| 250 |
|
| (2,086 | ) |
| (7,518 | ) | ||||
| Net cash used in investing activities of continuing operations |
| (414,806 | ) |
| (19,210 | ) |
| (761,210 | ) |
| (116,936 | ) | ||||
| Net cash provided by (used in) investing activities of discontinued operations |
| - |
|
| (6,474 | ) |
| 2,074,734 |
|
| (15,915 | ) | ||||
| Net cash (used in) provided by investing activities |
| (414,806 | ) |
| (25,684 | ) |
| 1,313,524 |
|
| (132,851 | ) | ||||
| Financing Activities: | ||||||||||||||||
| Payments on borrowings |
| - |
|
| (20,000 | ) |
| - |
|
| (240,000 | ) | ||||
| Proceeds from borrowings |
| - |
|
| 20,000 |
|
| - |
|
| 240,000 |
| ||||
| Payments of term loan |
| - |
|
| - |
|
| - |
|
| (500,000 | ) | ||||
| Payments of senior unsecured notes |
| (5,835 | ) |
| (50,404 | ) |
| (523,808 | ) |
| (57,876 | ) | ||||
| Payment of debt issuance costs |
| - |
|
| - |
|
| (15 | ) |
| - |
| ||||
| Settlement of cash flow hedges |
| - |
|
| - |
|
| - |
|
| (762 | ) | ||||
| Net (payments) proceeds on other credit facilities |
| (895 | ) |
| (810 | ) |
| 6,323 |
|
| (1,292 | ) | ||||
| Payments for acquisition-related contingent consideration |
| - |
|
| - |
|
| (10,117 | ) |
| (5 | ) | ||||
| Proceeds from issuance of common stock under stock plans |
| 623 |
|
| 7,860 |
|
| 4,344 |
|
| 14,114 |
| ||||
| Purchases of common stock |
| (4,868 | ) |
| (24,501 | ) |
| (388,882 | ) |
| (80,638 | ) | ||||
| Dividends paid |
| (8,639 | ) |
| (8,842 | ) |
| (34,966 | ) |
| (35,344 | ) | ||||
| Net cash used in financing activities of continuing operations |
| (19,614 | ) |
| (76,697 | ) |
| (947,121 | ) |
| (661,803 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
| 14,222 |
|
| 17,657 |
|
| (14,048 | ) |
| (33,747 | ) | ||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash |
| (223,585 | ) |
| 54,434 |
|
| 443,627 |
|
| (148,591 | ) | ||||
| Cash, cash equivalents, and restricted cash at beginning of period |
| 1,137,958 |
|
| 416,312 |
|
| 470,746 |
|
| 619,337 |
| ||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 914,373 |
| $ | 470,746 |
| $ | 914,373 |
| $ | 470,746 |
| ||||
| Supplemental disclosure of cash flow information: | ||||||||||||||||
| Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows: | ||||||||||||||||
| Cash and cash equivalents | $ | 913,163 |
| $ | 454,358 |
| $ | 913,163 |
| $ | 454,358 |
| ||||
| Restricted cash included in other current assets |
| 1,210 |
|
| 1,040 |
|
| 1,210 |
|
| 1,040 |
| ||||
| Restricted cash included in other assets |
| - |
|
| 349 |
|
| - |
|
| 349 |
| ||||
| Cash and cash equivalents included in current assets of discontinued operations |
| - |
|
| 14,999 |
|
| - |
|
| 14,999 |
| ||||
| Total cash, cash equivalents and restricted cash | $ | 914,373 |
| $ | 470,746 |
| $ | 914,373 |
| $ | 470,746 |
| ||||
PREPARED IN ACCORDANCE WITH GAAP | ||||||||||||||||
| Revvity, Inc. and Subsidiaries | |||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) | |||||
Revvity | |||||
Three Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth from continuing operations | -6% | ||||
| Less: effect of foreign exchange rates | 1% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | -7% | ||||
| Less: effect of COVID products | -4% | ||||
| Non-COVID organic revenue growth from continuing operations | -3% | ||||
Life Sciences | |||||
Three Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth from continuing operations | -8% | ||||
| Less: effect of foreign exchange rates | 1% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | -9% | ||||
Diagnostics | |||||
Three Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth from continuing operations | -4% | ||||
| Less: effect of foreign exchange rates | 1% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | -6% | ||||
| Less: effect of COVID products | -8% | ||||
| Non-COVID organic revenue growth from continuing operations | 3% | ||||
(1) amounts may not sum due to rounding | |||||
| Revvity, Inc. and Subsidiaries | |||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1) | |||||
Revvity | |||||
Twelve Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth from continuing operations | -17% | ||||
| Less: effect of foreign exchange rates | 0% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | -16% | ||||
| Less: effect of COVID products | -19% | ||||
| Non-COVID organic revenue growth from continuing operations | 2% | ||||
Life Sciences | |||||
Twelve Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth continuing operations | 0% | ||||
| Less: effect of foreign exchange rates | 0% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | 0% | ||||
Diagnostics | |||||
Twelve Months Ended | |||||
December 31, 2023 | |||||
| Organic revenue growth: | |||||
| Reported revenue growth continuing operations | -28% | ||||
| Less: effect of foreign exchange rates | -1% | ||||
| Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses | 0% | ||||
| Organic revenue growth from continuing operations | -27% | ||||
| Less: effect of COVID products | -32% | ||||
| Non-COVID organic revenue growth from continuing operations | 5% | ||||
(1) amounts may not sum due to rounding | |||||
Contacts
Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com
Media Contact:
Fara Goldberg (781) 663-5699
fara.goldberg@revvity.com
Read full story here
Editor Details
-
Company:
- Businesswire
